Stock 4593 HEALIOS K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Healios K.K.

Equities

4593

JP3835100003

Market Closed - Japan Exchange
Other stock markets
 07:00:00 26/06/2024 BST 		5-day change 1st Jan Change
195 JPY +5.41% Intraday chart for Healios K.K. +21.88% +18.18%
06-20 Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute MT
06-19 Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute
Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine
Healios K.K. Enters into Joint Research Agreement with AND Medical Group
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .
Japanese Shares Hit Fresh 52-Week Peak Ahead of Inflation Data
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan
Japanese Shares Finish Lower After Key Economic Data
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia
Healios K.K. Establish Subsidiary to Promote the Development
Healios and Saisei Ventures Enter into a Letter of Intent for eNK Research and Development
Healios Announces Establish Subsidiary for ENK Research and Development
Healios K.K. and Saisei Ventures Enter into A Letter of Intent and Establish Subsidiary for Ards Treatment Development
Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells
Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4593 Stock
  4. News Healios K.K.
  5. Other languages